Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

States’ Limits On OTC Dextromethorphan Sales Could Force Congress’ Hand

Executive Summary

US House legislation banning the sale of DXM OTCs to consumers under age 18 likely stands the same chance right now as previous versions that have failed, but CHPA expects an increasing number of state laws could spur future action.

You may also be interested in...



States With Age Restriction On OTC DXM Sales Number 17 – And Counting

Pennsylvania is 17th US state to limit sales of dextromethorphan OTCs to consumers 18 and older because teenagers' abuse of the ingredient for intoxicating effect remains a common problem.

States With Age Restriction On OTC DXM Sales Number 17 – And Counting

Pennsylvania is 17th US state to limit sales of dextromethorphan OTCs to consumers 18 and older because teenagers' abuse of the ingredient for intoxicating effect remains a common problem.

Perrigo Recalls Tamper-Resistant PSE Product Due To Contamination

FDA on Dec. 21 identified the recall as class II, for violative products that may cause temporary or medically reversible adverse health consequences though the probability of serious consequences is remote. Perrigo acquired the Zephrex-D brand and rights to the formulation in 2016.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel